MA38638A1 - Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations - Google Patents

Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations

Info

Publication number
MA38638A1
MA38638A1 MA38638A MA38638A MA38638A1 MA 38638 A1 MA38638 A1 MA 38638A1 MA 38638 A MA38638 A MA 38638A MA 38638 A MA38638 A MA 38638A MA 38638 A1 MA38638 A1 MA 38638A1
Authority
MA
Morocco
Prior art keywords
markers
disorders related
acid sphingomyelinase
asm
sphingomaelinase
Prior art date
Application number
MA38638A
Other languages
English (en)
Other versions
MA38638B1 (fr
Inventor
Wei-Lien Chuang
Gerald F Cox
X Kate Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38638A1 publication Critical patent/MA38638A1/fr
Publication of MA38638B1 publication Critical patent/MA38638B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012Sphingomyelin phosphodiesterase (3.1.4.12)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08Sphingolipids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)

Abstract

La présente invention concerne des procédés de dépistage, de diagnostic, de suivi et/ou de traitement de troubles liés à la sphingomélinase acide (asm) comme la maladie de niemann-pick. En particulier, les procédés comprennent des techniques pour un diagnostic et/ou un traitement amélioré d'un trouble asm, par exemple au moyen d'une enzymothérapie de remplacement.
MA38638A 2013-06-07 2014-06-06 Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations MA38638B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832302P 2013-06-07 2013-06-07
PCT/US2014/041405 WO2014197859A1 (fr) 2013-06-07 2014-06-06 Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations

Publications (2)

Publication Number Publication Date
MA38638A1 true MA38638A1 (fr) 2017-02-28
MA38638B1 MA38638B1 (fr) 2018-03-30

Family

ID=51062988

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38638A MA38638B1 (fr) 2013-06-07 2014-06-06 Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations

Country Status (31)

Country Link
US (3) US10022428B2 (fr)
EP (2) EP3004896B1 (fr)
JP (4) JP6457501B2 (fr)
KR (3) KR102292298B1 (fr)
CN (2) CN115128287A (fr)
AU (4) AU2014274670B2 (fr)
BR (1) BR112015030099A2 (fr)
CA (1) CA2914751C (fr)
CL (1) CL2015003563A1 (fr)
CR (1) CR20150638A (fr)
DK (1) DK3004896T3 (fr)
EA (1) EA035342B1 (fr)
ES (1) ES2762608T3 (fr)
HK (1) HK1217534A1 (fr)
HR (1) HRP20192246T1 (fr)
HU (1) HUE047863T2 (fr)
IL (3) IL284102B2 (fr)
LT (1) LT3004896T (fr)
MA (1) MA38638B1 (fr)
MX (1) MX370570B (fr)
MY (1) MY185990A (fr)
NZ (1) NZ754328A (fr)
PH (1) PH12015502687A1 (fr)
PL (1) PL3004896T3 (fr)
PT (1) PT3004896T (fr)
RS (1) RS59677B1 (fr)
SG (2) SG11201509622WA (fr)
SI (1) SI3004896T1 (fr)
UA (1) UA120591C2 (fr)
WO (1) WO2014197859A1 (fr)
ZA (1) ZA201508630B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102292298B1 (ko) * 2013-06-07 2021-08-24 젠자임 코포레이션 산 스핑고미엘리나제 장애에 대한 마커 및 이의 용도
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病c型を予防または治療するための医薬組成物
JP7216075B2 (ja) * 2017-08-24 2023-01-31 サノフイ 酸性スフィンゴミエリナーゼ欠損症患者における骨状態異常の処置
CN111278859A (zh) 2017-10-02 2020-06-12 戴纳立制药公司 包含酶替代疗法酶的融合蛋白
WO2024026390A2 (fr) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions et méthodes de diagnostic, de traitement et de prévention de maladies lysosomales

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US5773278A (en) * 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
WO2002018539A2 (fr) 2000-08-25 2002-03-07 Lysometrix Corporation Procede permettant d'analyser l'activite des enzymes lysosomales
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2006214731A (ja) * 2005-02-01 2006-08-17 Institute Of Physical & Chemical Research スフィンゴミエリンの検出方法
US20090148877A1 (en) 2005-12-15 2009-06-11 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
SI3482767T1 (sl) 2009-08-28 2022-03-31 Icahn School Of Medicine At Mount Sinai Encimska nadomestna terapija s povečevanjem odmerkov za zdravljenje pomanjkanja kisle sfingomielinaze
JP2013002933A (ja) 2011-06-16 2013-01-07 Hitachi Plant Technologies Ltd 3次元測位システム
DK2780716T3 (da) * 2011-11-15 2019-10-14 Centogene Ag Fremgangsmåde til diagnose af Niemann-Pick sygdom
JP6660291B2 (ja) * 2013-05-14 2020-03-11 セントジーン アーゲー ニーマン・ピック病の診断のための方法
KR102292298B1 (ko) * 2013-06-07 2021-08-24 젠자임 코포레이션 산 스핑고미엘리나제 장애에 대한 마커 및 이의 용도

Also Published As

Publication number Publication date
EA035342B1 (ru) 2020-05-29
RS59677B1 (sr) 2020-01-31
US20160120958A1 (en) 2016-05-05
AU2018200977A1 (en) 2018-03-01
CL2015003563A1 (es) 2016-08-05
KR102292298B1 (ko) 2021-08-24
MX370570B (es) 2019-12-17
US11998592B2 (en) 2024-06-04
US10888607B2 (en) 2021-01-12
KR20210104177A (ko) 2021-08-24
MY185990A (en) 2021-06-14
PL3004896T3 (pl) 2020-04-30
UA120591C2 (uk) 2020-01-10
SI3004896T1 (sl) 2020-01-31
SG10201709925SA (en) 2017-12-28
EA201592265A1 (ru) 2016-04-29
DK3004896T3 (da) 2020-01-06
NZ754328A (en) 2021-12-24
AU2014274670B2 (en) 2017-11-09
KR20210031541A (ko) 2021-03-19
PH12015502687A1 (en) 2016-03-07
LT3004896T (lt) 2020-01-10
JP2021075544A (ja) 2021-05-20
AU2023201062A1 (en) 2023-03-23
US20210162021A1 (en) 2021-06-03
AU2018200977B2 (en) 2020-07-23
JP6457501B2 (ja) 2019-01-23
AU2014274670A1 (en) 2016-01-07
JP2016526050A (ja) 2016-09-01
PT3004896T (pt) 2019-12-23
EP3004896A1 (fr) 2016-04-13
MX2015016844A (es) 2016-04-04
EP3584580A1 (fr) 2019-12-25
HUE047863T2 (hu) 2020-05-28
HRP20192246T1 (hr) 2020-03-06
CR20150638A (es) 2016-02-08
CA2914751A1 (fr) 2014-12-11
NZ715001A (en) 2021-10-29
SG11201509622WA (en) 2015-12-30
JP2024038145A (ja) 2024-03-19
IL284102B2 (en) 2023-04-01
JP2019089767A (ja) 2019-06-13
JP7414750B2 (ja) 2024-01-16
HK1217534A1 (zh) 2017-01-13
IL284102B (en) 2022-12-01
EP3004896B1 (fr) 2019-09-18
KR20160018651A (ko) 2016-02-17
IL284102A (en) 2021-07-29
BR112015030099A2 (pt) 2017-07-25
AU2020257114B2 (en) 2023-03-16
IL298675A (en) 2023-01-01
US20180289778A1 (en) 2018-10-11
ES2762608T3 (es) 2020-05-25
CA2914751C (fr) 2023-10-03
KR102228367B1 (ko) 2021-03-16
MA38638B1 (fr) 2018-03-30
WO2014197859A1 (fr) 2014-12-11
IL242964B (en) 2021-07-29
JP6835806B2 (ja) 2021-02-24
CN105474017A (zh) 2016-04-06
KR102434244B1 (ko) 2022-08-19
US10022428B2 (en) 2018-07-17
CN115128287A (zh) 2022-09-30
ZA201508630B (en) 2020-01-29
AU2020257114A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
MA38638A1 (fr) Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations
EP2987807A3 (fr) Anticorps dirigés contre tau phosphorylée
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA40662A1 (fr) Anticorps contre tigit
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
MX356800B (es) Anticuerpo tau humanizado.
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
MA38478A1 (fr) Anticorps anti-pac1 humains
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA35125B1 (fr) Alpha glucosidase acide modifiee a traitement accelere
MA40224B1 (fr) Anticorps se liant aux protofibrilles ass améliorés
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
ES2618506T3 (es) Marcador epigenético para la identificación de linfocitos T CD3CD4 positivos
EP3988673A3 (fr) Variants de tnfsf15 et dcr3 associés à la maladie de crohn
MA38161A1 (fr) Anticorps anti-bmp-6
WO2015013508A3 (fr) Procédés permettant de diagnostiquer et de traiter une maladie du système immunitaire
MA37670B1 (fr) Anticorps anti-transglutaminase 2
MX2021010467A (es) Biomarcadores para dolencias articulares y usos de estos.